A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease

Stopped Posdinemab did not achieve statistical significance in slowing clinical decline

Conditions

• Alzheimer Disease
• Cognitive Dysfunction
• Dementia

Interventions

• DRUG: JNJ-63733657
• DRUG: Placebo

Sponsor

Janssen Research & Development, LLC